Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Diluted Average) (2019 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $65.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 6.54% to $65.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $65.0 million, a 6.54% increase, with the full-year FY2025 number at $65.0 million, up 6.54% from a year prior.
  • Shares Outstanding (Diluted Average) was $65.0 million for Q4 2025 at Rhythm Pharmaceuticals, down from $66.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $66.3 million in Q3 2025 to a low of $48.5 million in Q1 2021.
  • A 5-year average of $56.6 million and a median of $57.2 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 13.86% in 2021, then increased 0.38% in 2022.
  • Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $49.6 million in 2021, then grew by 5.08% to $52.1 million in 2022, then increased by 10.65% to $57.7 million in 2023, then grew by 5.76% to $61.0 million in 2024, then grew by 6.54% to $65.0 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Shares Outstanding (Diluted Average) are $65.0 million (Q4 2025), $66.3 million (Q3 2025), and $63.4 million (Q2 2025).